Hal Galbraith Selected Research

bevirimat

10/2008	Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
9/2007	Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hal Galbraith Research Topics

Disease

1	Neoplasms (Cancer) 01/2019
1	Diarrhea 10/2008
1	Exanthema (Rash) 10/2008
1	Hyperbilirubinemia 10/2008
1	Infections 10/2008
1	Jaundice (Icterus) 10/2008
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2008
1	Headache (Headaches) 10/2008
1	HIV Infections (HIV Infection) 09/2007

Drug/Important Bio-Agent (IBA)

2	bevirimatIBA 10/2008 - 09/2007
1	osimertinibIBA 01/2019
1	Atazanavir Sulfate (Reyataz)FDA Link 10/2008
1	BilirubinIBA 10/2008